Get started
Author

Jennifer T. McDevitt

Observed names: J. McDevitt, J. T. McDevitt, Jennifer McDevitt
OpenAlex ID: A5034408281
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
2019 · Ronan J. Kelly, Jeeyun Lee, et al. · Clinical Cancer Research · 132
PDF
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
2016 · Michael Pishvaian, Michael A. Morse, et al. · Clinical Colorectal Cancer · 96
Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2014 · Paul Haluska, Michael Menefee, et al. · Clinical Cancer Research · 64
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
2018 · David M. Hyman, Naiyer Rizvi, et al. · Clinical Cancer Research · 56
First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.
2020 · Sattva Swarup Neelapu, Javier Munoz, et al. · Journal of Clinical Oncology · 46
First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
2021 · Frederick Lundry Locke, Shahbaz Malik, et al. · Journal of Clinical Oncology · 26
Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
2018 · Ronan Joseph Kelly, Jeeyun Lee, et al. · Journal of Clinical Oncology · 14
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
2016 · O. Hamid, L.Q. Chow, et al. · Annals of Oncology · 13
PDF
Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC
2018 · Jamie Chaft, Byoung Chul Cho, et al. · Cancer Research · 10
A phase 1b/2, open-label study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas.
2015 · John D. Powderly, Martin Gutierrez, et al. · Journal of Clinical Oncology · 10
A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
2015 · Rom Samuel Leidner, Sandip Pravin Patel, et al. · Journal of Clinical Oncology · 9
Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
2012 · Ronald B. Natale, Naiyer A. Rizvi, et al. · Journal of Clinical Oncology · 9
Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).
2009 · Alan S. Wayne, Deepa Bhojwani, et al. · Blood · 9
Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox
2010 · Alan Wayne, Deepa Bhojwani, et al. · Blood · 8
Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.
2010 · R. J. Kreitman, M. S. Tallman, et al. · Journal of Clinical Oncology · 8
Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas.
2016 · Michael J. Pishvaian, Michael Morse, et al. · Journal of Clinical Oncology · 5
A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.
2017 · Brendan D. Curti, Todd Michael Bauer, et al. · Journal of Clinical Oncology · 3
A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
2014 · David Michael Hyman, Naiyer A. Rizvi, et al. · Journal of Clinical Oncology · 2
3LB MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors
2010 · M. Menefee, P. LoRusso, et al. · European Journal of Cancer Supplements · 2
Abstract 3606: Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity
2019 · Chan C. Whiting, Nick Stock, et al. · Cancer Research · 1
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Supplementary Materials from Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
2023 · David M. Hyman, Naiyer Rizvi, et al.
PDF
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
2023 · Paul Haluska, Michael Menefee, et al.
Works count: 31
Citation count: 523
H-index: 10
I10-index: 10
Year
Topic
Type